Long-Term Effects of Rosiglitazone on the Progressive Decline in Renal Function in Patients With Type 2 Diabetes
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Thiazolidinediones reduce urinary albumin excretion and may prevent the development of renal injury. We evaluated the long-term effects of rosiglitazone on the progression of renal dysfunction in patients with type 2 diabetes mellitus. Methods: We enrolled patients with type 2 diabetes mellitus who initially had normal or mildly impaired renal function, defined as an estimated glomerular filtration rate (eGFR) of 60-120 ㎖/min per 1.73 ㎡, and normoalbuminuria. Patients were divided into two groups according to their use of rosiglitazone during 3 years of follow-up: those treated with rosiglitazone (rosiglitazone group, n=52) and those treated without rosiglitazone (control group, n=85). Progression of renal dysfunction was defined as a decrease in eGFR of ≥9 ㎖/min per 1.73 ㎡ after 3 years. Results: A greater difference was observed in the decrease in eGFR between the rosiglitazone and control groups after 3 years (3.8±9.9 vs. 12.6±10.5 ㎖/min per 1.73 ㎡, p<0.001). Seventeen of 52 (32.7%) patients in the rosiglitazone group and 53 of 85 (62.3%) patients in the control group showed progression of renal dysfunction (p=0.001). The progressors had a longer duration of diabetes (6.7±5.9 vs. 3.9±4.1 years, p=0.002), higher HbA1c levels (7.4±1.8 vs. 6.8±1.3%, p=0.023), and less frequent use of rosiglitazone (24.2 vs. 52.2%, p<0.001) compared to non-progressors. Multiple logistic regression analysis revealed that the use of rosiglitazone was a significant and independent predictor of the progression of renal dysfunction. Conclusions: This study suggests that rosiglitazone theatment slows the progressive deterioration of renal function in patients with type 2 diabetes.
Abstract
Background/Aims: Thiazolidinediones reduce urinary albumin excretion and may prevent the development of renal injury. We evaluated the long-term effects of rosiglitazone on the progression of renal dysfunction in patients with type 2 diabetes mellitus. Methods: We enrolled patients with type 2 diabetes mellitus who initially had normal or mildly impaired renal function, defined as an estimated glomerular filtration rate (eGFR) of 60-120 ㎖/min per 1.73 ㎡, and normoalbuminuria. Patients were divided into two groups according to their use of rosiglitazone during 3 years of follow-up: those treated with rosiglitazone (rosiglitazone group, n=52) and those treated without rosiglitazone (control group, n=85). Progression of renal dysfunction was defined as a decrease in eGFR of ≥9 ㎖/min per 1.73 ㎡ after 3 years. Results: A greater difference was observed in the decrease in eGFR between the rosiglitazone and control groups after 3 years (3.8±9.9 vs. 12.6±10.5 ㎖/min per 1.73 ㎡, p<0.001). Seventeen of 52 (32.7%) patients in the rosiglitazone group and 53 of 85 (62.3%) patients in the control group showed progression of renal dysfunction (p=0.001). The progressors had a longer duration of diabetes (6.7±5.9 vs. 3.9±4.1 years, p=0.002), higher HbA1c levels (7.4±1.8 vs. 6.8±1.3%, p=0.023), and less frequent use of rosiglitazone (24.2 vs. 52.2%, p<0.001) compared to non-progressors. Multiple logistic regression analysis revealed that the use of rosiglitazone was a significant and independent predictor of the progression of renal dysfunction. Conclusions: This study suggests that rosiglitazone theatment slows the progressive deterioration of renal function in patients with type 2 diabetes.
참고문헌 (23)
- Buckingham RE, "Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats", Diabetes, 47, pp.1326~1334 (1998)
- Yamashita H, "Thiazolidinedione derivatives ameliorate albuminuria in streptozotocin-induced diabetic spontaneous hypertensive rat", Metabolism, 51, pp.403~408 (2002)
- Imano E, "Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy", Diabetes Care, 21, pp.2135~2139 (1998)
- Bakris G, "Rosiglitazone reduces urinary albumin excretion in type II diabetes", J Hum Hypertens, 17, pp.7~12 (2003)
- Pistrosch F, "Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients", Diabetes, 54, pp.2206~2211 (2005)
- Bakris GL, "Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria", J Hypertens, 24, pp.2047~2055 (2006)
- Miyazaki Y, "Rosiglitazone decreases albuminuria in type 2 diabetic patients", Kidney Int, 72, pp.1367~1373 (2007)
- Schernthaner G, "Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial", Clin Endorinol Metab, 89, pp.6068~6079 (2004)
- Matthews DR, "Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study", Diabetes Metab Res Rev, 21, pp.167~174 (2005)
- Agarwal R, "A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy", Kidney Int, 68, pp.285~292 (2005)
- Jin HM, "Renoprotection provided by losartan in combination with pioglitazone is superior to renoprotection provided by losartan alone in patients with type 2 diabetic nephropathy", Kidney Blood Press Res, 30, pp.203~211 (2007)
- American Diabetes Association, "of medical care in diabetes: 2006", Diabetes Care, 29, pp.s4~s42 (2006)
- Kramer HJ, "Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus", JAMA, 289, pp.3273~3277 (2003)
- MacIsaac RJ, "Nonalbuminuric renal insufficiency in type 2 diabetes", Diabetes Care, 27, pp.195~200 (2004)
- New JP, "Assessing the prevalence, monitoring and management of chronic kidney disease in patients with diabetes compared with those without diabetes in general practice", Diabet Med, 24, pp.364~369 (2007)
- Vervoort G, "Assessment of glomerular filtration rate in healthy subjects and normoalbuminuric diabetic patients: validity of a new (MDRD) prediction equation", Nephrol Dial Transplant, 17, pp.1909~1913 (2002)
- Klein R, "Brazy PC. The 10- year incidence of renal insufficiency in people with type 1 diabetes", Diabetes Care, 22, pp.743~751 (1999)
- Levey AS, "National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification", Ann Intern Med, 139, pp.137~147 (2003)
- Sarafidis PA, "Protection of the kidney by thiazolidinediones: an assessment from bench to bedside", Kidney Int, 70, pp.1223~1233 (2006)
- Sakharova OV, "Pathogenesis of diabetic nephropathy: focus on transforming growth factor-beta and\ connective tissue growth factor", Curr Opin Nephrol Hypertens, 10, pp.727~738 (2001)
- Perico N, "Inhibition of TGF-beta expression: a novel role for thiazolidinediones to implement renoprotection in diabetes", Kidney Int, 72, pp.1419~1421 (2007)
- Ohga S, "Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activation", Am J Physiol Renal Physiol, 292, pp.f1141~f1150 (2007)
- Chudleigh RA, "How reliable is estimation of glomerular filtration rate at diagnosis of type 2 diabetes?", Diabetes Care, 30, pp.300~305 (2007)